Benjamin Caulier

  • Post-doc; PhD, Msc
  • +47 22 78 23 16

Kreftforeningen

Education:

2014-2017: PhD in Biotechnology, Development of a non-integrative (protein vector) for the generation of clinical-grade induced pluripotent stem cells, Univ. Grenoble Alpes, TIMC-IMAG CNRS 5525, French Blood Bank, Grenoble, France

2015-2016: Label Research: Business, Industry & Innovation, Univ. Grenoble Alpes, Grenoble, France

2011-2013: Master degree in Molecular & Cell Biology, Specialty: Immunology, Microbiology & Infectiology, University Joseph Fourier, Grenoble, France

2010-2011: Bachelor degree in Engineering Sciences & Technology, Specialty: Risk Management, Quality Assurance & Environment, IRIAF, Niort, France

2008-2010: Undergraduate in Biology (DUT), Specialty: Environment

Research interests/projects:

Cancer immunotherapy, novel cellular strategies (development of CARs, TCR redirected cells), biotechnological engineering, induced pluripotent stem cells-based modeling

Work experience:

2020-Present: Postdoc, Development of CAR therapy, Department of Cellular Therapy, OUS-Radiumhospitalet, Oslo, Norway

2017-2019: Postdoc, Development of a therapeutic type-3 adenoviral-like particle (dodecamer) for the treatment of acute myeloid leukemia. Departments of Cellular Hematology & Pediatric Oncology, Grenoble Alpes Hospital, Institute for Advanced Biosciences, TIMC-IMAG, Univ. Grenoble Alpes, Grenoble, France

2014-2017: PhD student, Development of a non-integrative (protein vector) for the generation of clinical-grade induced pluripotent stem cells. TIMC-IMAG CNRS 5525, Team Experimental Recombinant Therapy, French Blood Bank, Univ. Grenoble Alpes, Grenoble, France

2012-2013: Intern, Induction of patient-specific cytotoxic T lymphocytes against non-small cell lung cancer (NSCLC) with a therapeutic allogeneic plasmacytoid dendritic cell line (vaccine). Institute for Advanced Biosciences INSERM U1209, Team Immunobiology & Cancer Immunotherapy, French Blood Bank, Univ. Grenoble Alpes, Grenoble.

2011-2012: Intern, Induction of cytotoxic T lymphocytes against viruses & melanoma cancer with a therapeutic allogeneic plasmacytoid dendritic cell line (vaccine). Institute for Advanced Biosciences INSERM U1209, Team Immunobiology & Cancer Immunotherapy, French Blood Bank, Univ. Grenoble Alpes, Grenoble.

 

 

Publications 2017

Caulier B, Berthoin L, Coradin H, Garban F, Dagher MC, Polack B, Toussaint B, Lenormand JL, Laurin D (2017)
Targeted release of transcription factors for human cell reprogramming by ZEBRA cell-penetrating peptide
Int J Pharm, 529 (1-2), 65-74
DOI 10.1016/j.ijpharm.2017.06.073, PubMed 28647433

Publications 2016

Berthoin L, Toussaint B, Garban F, Le Gouellec A, Caulier B, Polack B, Laurin D (2016)
Targeted release of transcription factors for cell reprogramming by a natural micro-syringe
Int J Pharm, 513 (1-2), 678-687
DOI 10.1016/j.ijpharm.2016.09.081, PubMed 27697633

Aug 6, 2020 Page visits: 78